BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 33259637)

  • 1. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer.
    White AA; Lee DN; Mazzola E; Kucukak S; Polhemus E; Jaklitsch MT; Mentzer SJ; Wee JO; Bueno R; Swanson SJ
    J Surg Oncol; 2021 Feb; 123(2):579-586. PubMed ID: 33259637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.
    Kumar A; Srinivasan D; Potter AL; Mathey-Andrews C; Lanuti M; Martin LW; Jeffrey Yang CF
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1895-1905.e2. PubMed ID: 37722622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of adherence to the Commission on Cancer lung cancer quality measures.
    Odell DD; Feinglass J; Engelhardt K; Papastefan S; Meyerson SL; Bharat A; DeCamp MM; Bilimoria KY
    J Thorac Cardiovasc Surg; 2019 Mar; 157(3):1219-1235. PubMed ID: 31343410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.
    Pilon Y; Rokah M; Seitlinger J; Sepesi B; Rayes RF; Cools-Lartigue J; Najmeh S; Sirois C; Mulder D; Ferri L; Abdulkarim B; Ezer N; Fraser R; Camilleri-Broët S; Fiset PO; Wong A; Sud S; Langleben A; Agulnik J; Pepe C; Shieh B; Hirsh V; Ofiara L; Owen S; Spicer JD
    Clin Lung Cancer; 2024 May; 25(3):e133-e144.e4. PubMed ID: 38378398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of Selected Patients with IIIA-N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection.
    Fu F; Sun W; Bai J; Deng C; Zheng D; Li Y; Zhang Y; Chen H
    Ann Surg Oncol; 2023 Dec; 30(13):8261-8270. PubMed ID: 37644250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
    Du C; Chen Y; Zhou Y; Zheng D; Zhao J; Tang J; Wu Y; Tu Z
    BMC Cancer; 2023 Dec; 23(1):1260. PubMed ID: 38129808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront surgery for N2 NSCLC: a large retrospective multicenter cohort study.
    Campisi A; Catelli C; Gabryel P; Giovannetti R; Dell'Amore A; Kasprzyk M; Piwkowski C; Infante M
    Gen Thorac Cardiovasc Surg; 2023 Dec; 71(12):715-722. PubMed ID: 37179506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes Of Surgically Treated N2-Positive Non-Small Cell Lung Cancer.
    Rei J; Castro P; Guerra M; Miranda J
    Port J Card Thorac Vasc Surg; 2024 Feb; 30(4):23-29. PubMed ID: 38345887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NEOSTAR trial and the current status of neoadjuvant therapy in non-small cell lung cancer.
    Sepesi B; Mehran R; Spicer J; Cascone T
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1936-1942. PubMed ID: 37923289
    [No Abstract]   [Full Text] [Related]  

  • 11. Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Ji W; Jiang Y; Li Y; Mao W; Teng L
    Neoplasma; 2024 Feb; 71(1):88-97. PubMed ID: 38506033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.
    Li L; He K; Zhou T; Xu Y; Pang J; Yu Q; Gao Y; Shi H; Zhu H; Li M; Yu J; Yuan S
    Mol Oncol; 2024 Feb; ():. PubMed ID: 38327028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients.
    Bellotti R; Paiella S; Primavesi F; Jäger C; Demir IE; Casciani F; Kornprat P; Wagner D; Rösch CS; Butturini G; Giardino A; Goretzky PE; Mogl M; Fahlbusch T; Kaiser J; Strobel O; Nießen A; Luu AM; Salvia R; Maglione M
    HPB (Oxford); 2023 Nov; 25(11):1411-1419. PubMed ID: 37563033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of superior segmentectomy versus lower lobectomy for superior segment Stage I non-small-cell lung cancer are equivalent: An analysis of 196 patients at a single, high volume institution.
    Dolan DP; White A; Mazzola E; Lee DN; Gill R; Kucukak S; Bueno R; Jaklitsch MT; Mentzer SJ; Swanson SJ
    J Surg Oncol; 2021 Feb; 123(2):570-578. PubMed ID: 33259656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment-a narrative review.
    Calvo V; Aliaga C; Carracedo C; Provencio M
    Transl Lung Cancer Res; 2021 Jan; 10(1):581-589. PubMed ID: 33569338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of radial margins after esophagectomy for esophageal cancer.
    Bravo-Iñiguez CE; He Z; Dezube AR; Mazzola E; Yelamanchili N; Zhao L; Bueno R; Swanson SJ; White A; Wiener DC; Jaklitsch MT; Wee JO
    Eur J Surg Oncol; 2021 Sep; 47(9):2313-2322. PubMed ID: 33714649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy and Surgical Resection for N1 Positive Non-small Cell Lung Cancer: Better Than Expected Outcomes.
    White A; Kucukak S; Lee DN; Mazzola E; Dolan D; Bueno R; Jaklitsch MT; Swanson SJ
    Semin Thorac Cardiovasc Surg; 2021; 33(4):1105-1111. PubMed ID: 33600992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
    Huynh C; Walsh LA; Spicer JD
    Transl Lung Cancer Res; 2021 Jan; 10(1):563-580. PubMed ID: 33569337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction treatment in patients with stage III non-small cell lung cancer.
    Palmero R; Vilariño N; Navarro-Martín A; Nadal E
    Transl Lung Cancer Res; 2021 Jan; 10(1):539-554. PubMed ID: 33569335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers.
    Cone EB; Marchese M; Paciotti M; Nguyen DD; Nabi J; Cole AP; Molina G; Molina RL; Minami CA; Mucci LA; Kibel AS; Trinh QD
    JAMA Netw Open; 2020 Dec; 3(12):e2030072. PubMed ID: 33315115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.